I added all the FAQ answers from BioHarp website to ibox....
Frequently Asked Questions:
Q: If I were to go to my doctor or physician, how do they determine my baseline readings? Is it in the same visit?
A: The same day. It takes about 2-3 minutes to establish your baseline readings and then the actual scan can be done in as little as 10-15 minutes.
Q: How is the baseline established for the proper reading of the BioHarp:
A: The process is started by "wanding" the body with the hand held unit. The data is then sent to the software and a "Baseline" cellular reading is established by the software program. This is a very simple process and very user friendly.
Q: Have there been any human trials?
A: Yes, the BioHarp has been tested on humans and further testing will continue.
Q: Will the company be submitting the BioHarp to the US FDA?
A: This will be done in accordance with the KFDA so as to speed up the process of approval.
Q: Will you be submitting the BioHarp to other countries FDA's or other agencies you plan to sell the BioHarp into?
A: Yes, we will always comply with the requirements of the country we will be selling the BioHarp to.
Q: Do you need approval to sell the BioHarp to horticulture or vetrinary markets?
A: Currently there are no restictions in these sectors and the BioHarp will be marketed and sold to these areas in the immediate future.
UPDATED DECEMBER 10, 2009
Q: Will the company be raising the Outstanding Shares past the 1,000,000,000?
A: No, definitely no. We have the proper structure for the company now and in our future move to a higher exchange.
Q: Will the company be doing a reverse split?
A: No, definitely no. With the anticipated sales we will have there is no need to explore that whatsoever. We've had so many inquiries to date from several countries expressing interest in purchasing the BioHarp that our share structure will support the aniticpated revenues.
Q: When will the company begin to see sales of the BioHarp?
A: We are working right now on getting the final production unit done and ready to go. We expect to sell the BioHarp to veterinarians, equine, and horticulture markets in the first quarter of 2010. We are not limited to KFDA, CE, or FDA approval to do this.
Q: Why didn't you just do a simple merger rather than an asset purchase?
A: For valuation. A merge would not have given us the proper valuation for the company's anticipated move to a higher exchange. By purchasing the asset, XTend now has a measureable value for the future audit of the company. This will be very important when we file the forms to move to a higher exchange.
Q: Does the company has sufficient cash reserves to execute the business plan?
A: Yes! We are ready to execute the plan we have worked so hard to establish.
Q: When will the website be updated?
A: As we just finished up the asset purchase, we ask for a little patience from our shareholders. We're working on many items and the website is one of them. Look for a more robust website within the next 30 days wherein we will also have video demonstrations of the BioHarp.
AI
